<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/allregs/css/uswds.min.css">
    <link rel="stylesheet" href="/allregs/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/allregs/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/allregs/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/parts/21CFR316.html">Part 316
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 316.27  Change in ownership of orphan-drug designation.
                            </h3>
                            <p class="depth1"><em>(a)</em> A sponsor may transfer ownership of or any beneficial interest in the orphan-drug designation of a drug to a new sponsor. At the time of the transfer, the new and former owners are required to submit the following information to FDA:</p><p class="depth2"><em>(1)</em> The former owner or assignor of rights shall submit a letter or other document that states that all or some rights to the orphan-drug designation of the drug have been transferred to the new owner or assignee and that a complete copy of the request for orphan-drug designation, including any amendments to the request, supplements to the granted request, and correspondence relevant to the orphan-drug designation, has been provided to the new owner or assignee.</p><p class="depth2"><em>(2)</em> The new owner or assignee of rights shall submit a statement accepting orphan-drug designation and a letter or other document containing the following:</p><p class="depth3"><em>(i)</em> The date that the change in ownership or assignment of rights is effective;</p><p class="depth3"><em>(ii)</em> A statement that the new owner has a complete copy of the request for orphan-drug designation including any amendments to the request, supplements to the granted request, and correspondence relevant to the orphan-drug designation; and</p><p class="depth3"><em>(iii)</em> A specific description of the rights that have been assigned and those that have been reserved. This may be satisfied by the submission of either a list of rights assigned and reserved or copies of all relevant agreements between assignors and assignees; and</p><p class="depth3"><em>(iv)</em> The name and address of a new primary contact person or resident agent.</p><p class="depth1"><em>(b)</em> No sponsor may relieve itself of responsibilities under the Orphan Drug Act or under this part by assigning rights to another person without:</p><p class="depth2"><em>(1)</em> Assuring that the sponsor or the assignee will carry out such responsibilities; or</p><p class="depth2"><em>(2)</em> Obtaining prior permission from FDA.
[57 FR 62085, Dec. 29, 1992; 58 FR 6167, Jan. 26, 1993]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§.
          Code available <a href="https://github.com/anthonygarvan/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5
      </div>
    </div>
  </footer>
  </body>
</html>
